Dopamine D2 receptor occupancy and clinical effects: A systematic review and pooled analysis

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 497-502

  Uchida, Hiroyuki ^a,b   Takeuchi, Hiroyoshi ^a   Graff Guerrero, Ariel ^b,c   Suzuki, Takefumi ^b,c   Watanabe, Koichiro ^a   Mamo, David C ^b,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

antipsychotic; dopamine; dopamine D2 receptor; positron emission tomography; schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; ZIPRASIDONE; DOPAMINE 2 RECEPTOR;

ACCURACY; BRIEF PSYCHIATRIC RATING SCALE; CALCULATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; EMBASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); METABOLISM; METHODOLOGY; PHYSIOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 79960616055     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182214aad     Document Type: Review

References (42)

1. Uchida H, Suzuki T, Mamo DC, et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry. 2008;16:584-593.
2. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090. (Pubitemid 37464954)
3. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15:19S-23S.
4. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157: 514-520. (Pubitemid 30191189)
5. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
6. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33:298-304. (Pubitemid 350243350)
7. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825. (Pubitemid 38625334)
8. Reardon GT, Rifkin A, Schwartz A, et al. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry. 1989;146:726-729. (Pubitemid 19149582)
9. Meisenzahl EM, Schmitt G, Grunder G, et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry. 2008;41:169-175.
10. Zipursky RB, Christensen BK, Daskalakis Z, et al. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Can J Psychiatry. 2005;50:462-469. (Pubitemid 43161799)
11. Schonfeldt-Lecuona C, Juengling FD, Connemann BJ, et al. Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol. J Clin Psychopharmacol. 2004;24:97-98. (Pubitemid 38134175)
12. Stone JM, Davis JM, Leucht S, et al. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugsYan original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull. 2009;35: 789-797.
13. Catafau AM, Suarez M, Bullich S, et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage. 2009;46:447-458.
14. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
15. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
16. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
17. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676. (Pubitemid 19154942)
18. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247-265. (Pubitemid 40804771)
19. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009;7-14.
20. Alberg AJ, Park JW, Hager BW, et al. The use of "overall accuracy" to evaluate the validity of screening or diagnostic tests. J Gen Int Med. 2004;19:460-465. (Pubitemid 38638908)
21. Farde L, Wiesel FA, Jansson P, et al. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl). 1988;94:1-7. (Pubitemid 18009055)
22. Farde L, von Bahr C. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand. 1990;358:67-71. (Pubitemid 20297823)
23. Nordstrom AL, Farde L,Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227-235.
24. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153:948-950. (Pubitemid 26225470)
25. Kapur S, Zipursky R, Roy P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl). 1997;131:148-152. (Pubitemid 27261602)
26. Nordstrom AL, Nyberg S, Olsson H, et al. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry. 1998;55:283-284.
27. Kapur S, Zipursky RB. Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy. Arch Gen Psychiatry. 1998;55:666-668. (Pubitemid 28340358)
28. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921-928. (Pubitemid 28307604)
29. Sekine Y, Ouchi Y, Takei N, et al. Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain. J Clin Psychopharmacol. 2006;26:531-533. (Pubitemid 44401481)
30. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008;197:229-235.
31. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2008;22:49-68. (Pubitemid 350243366)
32. Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol. 2006;20:86-90.
33. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002;159:554-560. (Pubitemid 34274936)
34. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318-325.
35. Uchida H, Kapur S, Mulsant BH, et al. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009;17:255-263.
36. Uchida H, Rajji TK, Mulsant BH, et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009;29:571-575.
37. Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic responseVa double-blind PET study in schizophrenia. Neuropsychopharmacology. 2007;32:1209-1215. (Pubitemid 46788848)
38. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293. (Pubitemid 29077120)
39. Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:917-920.
40. Uchida H, Mamo DC, Mulsant BH, et al. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 2009;70:397-405.
41. Uchida H, Mamo DC. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther. 2009;86:360-362.
42. Uchida H, Suzuki T, Takeuchi H, et al. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull. 2009. [Epub ahead of print].